An Emerging Prospective of Antipsychotics for Treating Neurodegenerative Disorders.

IF 2.8 4区医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2025-01-01 DOI:10.2174/0113816128344910241211112452

Bhavna Kumar, Arpita Sahoo, Manmohan Singhal, Garima Varshney, Tripti Haldar, Vikas Bali

{"title":"An Emerging Prospective of Antipsychotics for Treating Neurodegenerative Disorders.","authors":"Bhavna Kumar, Arpita Sahoo, Manmohan Singhal, Garima Varshney, Tripti Haldar, Vikas Bali","doi":"10.2174/0113816128344910241211112452","DOIUrl":null,"url":null,"abstract":"<p><p>CNS illnesses specified by slow deprivation of especially preganglionic neurons, as opposed to the selective static neuronal loss caused by a toxic or metabolic condition, are known as Neurodegenerative disorders. Neurodegenerative disorders are differentiated clinically by behavioral or cognitive problems. The management and treatment of neurodegenerative disorders pose significant challenges, necessitating a multidimensional approach. While primarily designed for psychiatric conditions, antipsychotics have shown potential in ameliorating behavioral and psychological symptoms in neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. This review explores the existing literature, highlighting the potential benefits, risks, and considerations associated with incorporating antipsychotics into the treatment paradigm for neurodegenerative disorders. Additionally, it discusses the evolving landscape of personalized treatment strategies, emphasizing the need for a multidisciplinary approach to optimize patient outcomes in the complex realm of neurodegenerative disorder management.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":"1925-1938"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128344910241211112452","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

CNS illnesses specified by slow deprivation of especially preganglionic neurons, as opposed to the selective static neuronal loss caused by a toxic or metabolic condition, are known as Neurodegenerative disorders. Neurodegenerative disorders are differentiated clinically by behavioral or cognitive problems. The management and treatment of neurodegenerative disorders pose significant challenges, necessitating a multidimensional approach. While primarily designed for psychiatric conditions, antipsychotics have shown potential in ameliorating behavioral and psychological symptoms in neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. This review explores the existing literature, highlighting the potential benefits, risks, and considerations associated with incorporating antipsychotics into the treatment paradigm for neurodegenerative disorders. Additionally, it discusses the evolving landscape of personalized treatment strategies, emphasizing the need for a multidisciplinary approach to optimize patient outcomes in the complex realm of neurodegenerative disorder management.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗精神病药物治疗神经退行性疾病的新前景。

以神经节前神经元的缓慢丧失为特征的中枢神经系统疾病，与由毒性或代谢条件引起的选择性静态神经元丧失相反，被称为神经退行性疾病。神经退行性疾病在临床上可通过行为或认知问题来鉴别。神经退行性疾病的管理和治疗提出了重大挑战，需要一个多维的方法。虽然主要是为精神疾病设计的，但抗精神病药物已显示出改善神经退行性疾病（如阿尔茨海默氏症和帕金森病）的行为和心理症状的潜力。本综述探讨了现有文献，强调了将抗精神病药物纳入神经退行性疾病治疗范例的潜在益处、风险和注意事项。此外，它还讨论了个性化治疗策略的发展前景，强调需要多学科方法来优化神经退行性疾病管理复杂领域的患者结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.